Fady Malik, MD, PhD

Title(s)Volunteer Clinical Professor, Medicine
SchoolSchool of Medicine
Address505 Parnassus Avenue, #M1177A
San Francisco CA 94117
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    University of California, San Francisco Clinical Fellowship School of Medicine
    University of California, San Francisco Residency School of Medicine
    University of California, San FranciscoM.D.1994 Medicine
    University of California, San FranciscoPh.D.1993 Graduate Division (Neuroscience)

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Application of the ENCALS predictive survival model in assessing the effect of the 24/44 inclusion criteria in FORTITUDE-ALS. J Neuromuscul Dis. 2025 May 05; 22143602251336058. Simkins Lead T, Shefner JM, Kupfer S, Malik FI, Meng L, Rudnicki SA, Wei J, van Eijk RP. PMID: 40324960.
      View in: PubMed   Mentions:    Fields:    
    2. Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical Trial. JAMA Neurol. 2025 May 01; 82(5):477-485. Shefner JM, Cudkowicz ME, Genge A, Hardiman O, Al-Chalabi A, Andrews JA, Chio A, Corcia P, Couratier P, de Carvalho M, Heiman-Patterson T, Henderson RD, Ingre C, Johnston W, Ludolph A, Maragakis NJ, Miller TM, Mora JS, Petri S, Simmons Z, van den Berg LH, Zinman L, Kupfer S, Malik FI, Meng L, Simkins TJ, Wei J, Wolff AA, Rudnicki SA, COURAGE-ALS Study Group. PMID: 40126464; PMCID: PMC11933997.
      View in: PubMed   Mentions:    Fields:    Translation:CTClinical Trials
    3. A Characterization of the Nonclinical Pharmacology and Toxicology of Aficamten, a Reversible Allosteric Inhibitor of Cardiac Myosin. Int J Toxicol. 2025 Mar 20; 10915818251326466. Pugsley MK, Hwee DT, Winters BR, Wang J, Chin ER, Morgan BP, Malik FI. PMID: 40112881.
      View in: PubMed   Mentions:    Fields:    
    4. Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics. JACC Heart Fail. 2025 Feb; 13(2):346-357. Garcia-Pavia P, Bilen O, Burroughs M, Costabel JP, de Barros Correia E, Dybro AM, Elliott P, Lakdawala NK, Mann A, Nair A, Nassif ME, Poulsen SH, Reant P, Schulze PC, Wang A, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Meng L, Sohn R, Wohltman A, Fifer MA, MAPLE-HCM Study Investigators. PMID: 39909646.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Correction to "Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility". J Med Chem. 2025 Jan 09; 68(1):850. Romero A, Ashcraft L, Chandra A, DiMassa V, Cremin P, Collibee SE, Chuang C, Hartman J, Hwee DT, St Jean D, Malinowski J, DeBenedetto M, Moebius DC, Payette J, Vargas R, Yeoman J, Motani A, Reagan J, Malik FI, Morgan BP. PMID: 39722587; PMCID: PMC11726665.
      View in: PubMed   Mentions:    Fields:    
    6. Plasma neurofilament analysis in VITALITY-ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2025 Feb; 26(1-2):103-112. Simkins TJ, Kupfer S, Malik FI, Meng L, Rudnicki SA, Wei J, Shefner JM, Bowser R. PMID: 39513379.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    7. Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial. Eur Heart J. 2024 Nov 08; 45(42):4464-4478. Coats CJ, Masri A, Barriales-Villa R, Abraham TP, Brinkley DM, Claggett BL, Hagege A, Hegde SM, Ho CY, Kulac IJ, Lee MMY, Maron MS, Olivotto I, Owens AT, Solomon SD, Tfelt-Hansen J, Watkins H, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Januzzi JL. PMID: 39217447; PMCID: PMC11544315.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM. J Am Coll Cardiol. 2024 Nov 05; 84(19):1839-1849. Masri A, Choudhury L, Barriales-Villa R, Elliott P, Maron MS, Nassif ME, Oreziak A, Owens AT, Saberi S, Tower-Rader A, Rader F, Garcia-Pavia P, Olivotto I, Nagueh SF, Wang A, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Melloni C, Meng L, Wei J, Sherrid MV, Abraham TP, FOREST-HCM Investigators. PMID: 39477631.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical Trial. JAMA Cardiol. 2024 Nov 01; 9(11):990-1000. Lee MMY, Masri A, Nassif ME, Barriales-Villa R, Abraham TP, Claggett BL, Coats CJ, Gimeno JR, Kulac IJ, Landsteiner I, Ma C, Maron MS, Olivotto I, Owens AT, Solomon SD, Veselka J, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Lewis GD, SEQUOIA-HCM Investigators. PMID: 39230885; PMCID: PMC11375526.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    10. Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM. J Am Coll Cardiol. 2024 Nov 05; 84(19):1821-1831. Maron MS, Masri A, Nassif ME, Barriales-Villa R, Abraham TP, Arad M, Cardim N, Choudhury L, Claggett B, Coats CJ, Düngen HD, Garcia-Pavia P, Hagège AA, Januzzi JL, Kulac I, Lee MMY, Lewis GD, Ma CS, Michels M, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins HC, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Olivotto I, SEQUOIA-HCM Investigators. PMID: 39352339.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    11. Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy. J Am Coll Cardiol. 2024 Nov 05; 84(19):1806-1817. Masri A, Cardoso RN, Abraham TP, Claggett BL, Coats CJ, Hegde SM, Kulac IJ, Lee MMY, Maron MS, Merkely B, Michels M, Olivotto I, Oreziak A, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Solomon SD, Wohltman A, Kwong RY, Kramer CM, SEQUOIA-HCM Investigators. PMID: 39217563.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    12. Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM. J Am Coll Cardiol. 2024 Nov 05; 84(19):1773-1785. Sherrod CF, Saberi S, Nassif ME, Claggett BL, Coats CJ, Garcia-Pavia P, Januzzi JL, Lewis GD, Ma C, Maron MS, Miao ZM, Olivotto I, Veselka J, Butzner M, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Spertus JA. PMID: 39217569; PMCID: PMC11975529.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    13. Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2024 Nov 05; 84(19):1789-1802. Hegde SM, Claggett BL, Wang X, Jering K, Prasad N, Roshanali F, Masri A, Nassif ME, Barriales-Villa R, Abraham TP, Cardim N, Coats CJ, Kramer CM, Maron MS, Michels M, Olivotto I, Saberi S, Jacoby DL, Heitner SB, Kupfer S, Meng L, Wohltman A, Malik FI, Solomon SD, SEQUOIA-HCM Investigators. PMID: 39217556.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    14. Super-relaxed myosins contribute to respiratory muscle hibernation in mechanically ventilated patients. Sci Transl Med. 2024 Jul 31; 16(758):eadg3894. van den Berg M, Shi Z, Claassen WJ, Hooijman P, Lewis CTA, Andersen JL, van der Pijl RJ, Bogaards SJP, Conijn S, Peters EL, Begthel LPL, Uijterwijk B, Lindqvist J, Langlais PR, Girbes ARJ, Stapel S, Granzier H, Campbell KS, Ma W, Irving T, Hwee DT, Hartman JJ, Malik FI, Paul M, Beishuizen A, Ochala J, Heunks L, Ottenheijm CAC. PMID: 39083588; PMCID: PMC11586073.
      View in: PubMed   Mentions: 3     Fields:    
    15. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM. J Am Heart Assoc. 2024 Aug 06; 13(15):e035993. Coats CJ, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, Choudhury L, Claggett B, Düngen HD, Garcia-Pavia P, Hagège AA, Januzzi JL, Lee MMY, Lewis GD, Ma CS, Maron MS, Miao ZM, Michels M, Olivotto I, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins H, Jacoby DL, German P, Heitner SB, Kupfer S, Lutz JD, Malik FI, Meng L, Wohltman A, Abraham TP, SEQUOIA-HCM Investigators *. PMID: 39056349; PMCID: PMC11964075.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    16. Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy. Nat Cardiovasc Res. 2024 Aug; 3(8):1003-1016. Hartman JJ, Hwee DT, Robert-Paganin J, Chuang C, Chin ER, Edell S, Lee KH, Madhvani R, Paliwal P, Pernier J, Sarkar SS, Schaletzky J, Schauer K, Taheri KD, Wang J, Wehri E, Wu Y, Houdusse A, Morgan BP, Malik FI. PMID: 39196032; PMCID: PMC11358156.
      View in: PubMed   Mentions: 2  Translation:AnimalsCells
    17. Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy: A 36-week analysis from FOREST-HCM. Eur J Heart Fail. 2024 Sep; 26(9):1993-1998. Masri A, Barriales-Villa R, Elliott P, Nassif ME, Oreziak A, Owens AT, Tower-Rader A, Heitner SB, Kupfer S, Malik FI, Melloni C, Meng L, Wei J, Saberi S, ?on behalf of the FOREST-HCM Investigators. PMID: 39023326.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. Cardiac myosin inhibitor, CK-586, minimally reduces systolic function and ameliorates obstruction in feline hypertrophic cardiomyopathy. Sci Rep. 2024 05 27; 14(1):12038. Rivas VN, Crofton AE, Jauregui CE, Wouters JR, Yang BS, Wittenburg LA, Kaplan JL, Hwee DT, Murphy AN, Morgan BP, Malik FI, Harris SP, Stern JA. PMID: 38802475; PMCID: PMC11130313.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    19. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2024 05 30; 390(20):1849-1861. Maron MS, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, Choudhury L, Claggett B, Coats CJ, Düngen HD, Garcia-Pavia P, Hagège AA, Januzzi JL, Lee MMY, Lewis GD, Ma CS, Michels M, Olivotto I, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins H, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Abraham TP, SEQUOIA-HCM Investigators. PMID: 38739079.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    20. Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility. J Med Chem. 2024 May 23; 67(10):7825-7835. Romero A, Ashcraft L, Chandra A, DiMassa V, Cremin P, Collibee SE, Chuang C, Hartman J, Hwee DT, St Jean D, Malinowski J, DeBenedetto M, Moebius D, Payette J, Vargas R, Yeoman J, Motani A, Reagan J, Malik FI, Morgan BP. PMID: 38729623; PMCID: PMC11129190.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    21. Pathogenic TNNI1 variants disrupt sarcomere contractility resulting in hypo- and hypercontractile muscle disease. Sci Transl Med. 2024 Apr 03; 16(741):eadg2841. Donkervoort S, van de Locht M, Ronchi D, Reunert J, McLean CA, Zaki M, Orbach R, de Winter JM, Conijn S, Hoomoedt D, Neto OLA, Magri F, Viaene AN, Foley AR, Gorokhova S, Bolduc V, Hu Y, Acquaye N, Napoli L, Park JH, Immadisetty K, Miles LB, Essawi M, McModie S, Ferreira LF, Zanotti S, Neuhaus SB, Medne L, ElBagoury N, Johnson KR, Zhang Y, Laing NG, Davis MR, Bryson-Richardson RJ, Hwee DT, Hartman JJ, Malik FI, Kekenes-Huskey PM, Comi GP, Sharaf-Eldin W, Marquardt T, Ravenscroft G, Bönnemann CG, Ottenheijm CAC. PMID: 38569017.
      View in: PubMed   Mentions: 1     Fields:    
    22. Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4. J Card Fail. 2024 Nov; 30(11):1439-1448. Masri A, Sherrid MV, Abraham TP, Choudhury L, Garcia-Pavia P, Kramer CM, Barriales-Villa R, Owens AT, Rader F, Nagueh SF, Olivotto I, Saberi S, Tower-Rader A, Wong TC, Coats CJ, Watkins H, Fifer MA, Solomon SD, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Meng L, Sohn RL, Wohltman A, Maron MS, REDWOOD-HCM Investigators. PMID: 38493832.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    23. Cardiac Troponin Activator CK-963 Increases Cardiac Contractility in Rats. J Med Chem. 2024 May 23; 67(10):7859-7869. Collibee SE, Romero A, Muci AR, Hwee DT, Chuang C, Hartman JJ, Motani AS, Ashcraft L, DeRosier A, Grillo M, Lu Q, Malik FI, Morgan BP. PMID: 38451215; PMCID: PMC11129196.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    24. Tirasemtiv enhances submaximal muscle tension in an Acta1:p.Asp286Gly mouse model of nemaline myopathy. J Gen Physiol. 2024 Apr 01; 156(4). Galli RA, Borsboom TC, Gineste C, Brocca L, Rossi M, Hwee DT, Malik FI, Bottinelli R, Gondin J, Pellegrino MA, de Winter JM, Ottenheijm CAC. PMID: 38376469; PMCID: PMC10876480.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    25. Tricuspid Regurgitation and Clinical Outcomes in Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2024 Mar; 12(3):552-563. Adamo M, Metra M, Claggett BL, Miao ZM, Diaz R, Felker GM, McMurray JJV, Solomon SD, Biering-Sørensen T, Divanji PH, Heitner SB, Kupfer S, Malik FI, Teerlink JR, GALACTIC-HF Investigators and Patients. PMID: 38300212.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    26. Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study. J Card Fail. 2024 Jun; 30(6):755-763. Felker GM, Solomon SD, Metra M, Mcmurray JJV, Diaz R, Claggett B, Lanfear DE, Vandekerckhove H, Biering-Sørensen T, Lopes RD, Arias-Mendoza A, Momomura SI, Corbalan R, Ramires FJA, Zannad F, Heitner SB, Divanji PH, Kupfer S, Malik FI, Teerlink JR. PMID: 38215932.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    27. Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM Baseline Characteristics and Study Design. JACC Heart Fail. 2024 01; 12(1):199-215. Coats CJ, Maron MS, Abraham TP, Olivotto I, Lee MMY, Arad M, Cardim N, Ma CS, Choudhury L, Düngen HD, Garcia-Pavia P, Hagège AA, Lewis GD, Michels M, Oreziak A, Owens AT, Tfelt-Hansen J, Veselka J, Watkins HC, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Meng L, Wohltman A, Masri A, SEQUOIA-HCM Investigators. PMID: 38032573.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    28. Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF Trial. JACC Heart Fail. 2023 12; 11(12):1729-1738. Pabon M, Cunningham J, Claggett B, Felker GM, McMurray JJV, Metra M, Diaz R, Wang X, Arias-Mendoza A, Bonderman D, Crespo-Leiro M, Fonseca C, Goncalvesova E, Lund M, O'Meara E, Sliwa-Hahnle K, Malik FI, Solomon SD, Teerlink JR, GALACTIC-HF Investigators. PMID: 37831045.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    29. Rewarding Site-Based Research: A Step Toward Improving the Ecosystem of Heart Failure Clinical Trials. JACC Heart Fail. 2024 01; 12(1):226-228. Dimond MG, Fiuzat M, Mentz RJ, Lala-Trindade A, Whellan DJ, Walsh MN, Costanzo MR, Yehya A, Desvigne-Nickens P, Malik F, O'Connor CM, Bristow MR. PMID: 37804314.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    30. The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HF. J Card Fail. 2024 01; 30(1):26-35. Docherty KF, McMurray JJV, Diaz R, Felker GM, Metra M, Solomon SD, Adams KF, Böhm M, Brinkley DM, Echeverria LE, Goudev AR, Howlett JG, Lund M, Ponikowski P, Yilmaz MB, Zannad F, Claggett BL, Miao ZM, Abbasi SA, Divanji P, Heitner SB, Kupfer S, Malik FI, Teerlink JR. PMID: 37683911.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    31. Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trial. Amyotroph Lateral Scler Frontotemporal Degener. 2024 Feb; 25(1-2):162-169. Shefner JM, Jacobsen B, Kupfer S, Malik FI, Meng L, Wei J, Wolff AA, Rudnicki SA. PMID: 37641579.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    32. Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3. J Card Fail. 2023 11; 29(11):1576-1582. Owens AT, Masri A, Abraham TP, Choudhury L, Rader F, Symanski JD, Turer AT, Wong TC, Tower-Rader A, Coats CJ, Fifer MA, Olivotto I, Solomon SD, Watkins HC, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Meng L, Sohn R, Wohltman A, Maron MS, REDWOOD-HCM INVESTIGATORS. PMID: 37473912.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    33. COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success. Amyotroph Lateral Scler Frontotemporal Degener. 2023 08; 24(5-6):523-534. Shefner JM, Al-Chalabi A, Andrews JA, Chio A, De Carvalho M, Cockroft BM, Corcia P, Couratier P, Cudkowicz ME, Genge A, Hardiman O, Heiman-Patterson T, Henderson RD, Ingre C, Jackson CE, Johnston W, Lechtzin N, Ludolph A, Maragakis NJ, Miller TM, Mora Pardina JS, Petri S, Simmons Z, Van Den Berg LH, Zinman L, Kupfer S, Malik FI, Meng L, Simkins TJ, Wei J, Wolff AA, Rudnicki SA. PMID: 37254449.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    34. Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HF. JACC Heart Fail. 2023 05; 11(5):569-579. Lanfear DE, Njoroge JN, Adams KF, Anand I, Fang JC, Ramires F, Sliwa-Hahnle K, Badat A, Burgess L, Gorodeski EZ, Williams C, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon S, Miao ZM, Claggett BL, Heitner SB, Kupfer S, Malik FI, Teerlink JR. PMID: 36881396.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    35. Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trial. Eur J Heart Fail. 2023 02; 25(2):248-259. Docherty KF, McMurray JJV, Claggett BL, Miao ZM, Adams KF, Arias-Mendoza A, Cleland JGF, Diaz R, Echeverria Correa LE, Felker GM, Fonseca C, Li J, Metra M, Sliwa-Hahnle K, Solomon SD, Vandekerckhove HJ, Vinereanu D, Voors AA, Heitner SB, Kupfer S, Malik FI, Meng L, Teerlink JR. PMID: 36597719.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    36. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2023 01 03; 81(1):34-45. Maron MS, Masri A, Choudhury L, Olivotto I, Saberi S, Wang A, Garcia-Pavia P, Lakdawala NK, Nagueh SF, Rader F, Tower-Rader A, Turer AT, Coats C, Fifer MA, Owens A, Solomon SD, Watkins H, Barriales-Villa R, Kramer CM, Wong TC, Paige SL, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Abraham T, REDWOOD-HCM Steering Committee and Investigators. PMID: 36599608.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCTClinical Trials
    37. Effects of Aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathy. Sci Rep. 2023 01 02; 13(1):32. Sharpe AN, Oldach MS, Rivas VN, Kaplan JL, Walker AL, Kovacs SL, Hwee DT, Cremin P, Morgan BP, Malik FI, Harris SP, Stern JA. PMID: 36593243; PMCID: PMC9807554.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    38. Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. Eur Heart J. 2022 12 21; 43(48):5006-5016. Metra M, Pagnesi M, Claggett BL, Díaz R, Felker GM, McMurray JJV, Solomon SD, Bonderman D, Fang JC, Fonseca C, Goncalvesova E, Howlett JG, Li J, O'Meara E, Miao ZM, Abbasi SA, Heitner SB, Kupfer S, Malik FI, Teerlink JR. PMID: 35675469; PMCID: PMC9769958.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    39. Titin-truncating variants in hiPSC cardiomyocytes induce pathogenic proteinopathy and sarcomere defects with preserved core contractile machinery. Stem Cell Reports. 2023 01 10; 18(1):220-236. Huang G, Bisaria A, Wakefield DL, Yamawaki TM, Luo X, Zhang JA, Vigneault P, Wang J, Reagan JD, Oliverio O, Zhou H, Li CM, Vila OF, Wang S, Malik FI, Hartman JJ, Hale CM. PMID: 36525964; PMCID: PMC9860080.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    40. Pharmacokinetics of a single dose of Aficamten (CK-274) on cardiac contractility in a A31P MYBPC3 hypertrophic cardiomyopathy cat model. J Vet Pharmacol Ther. 2023 Jan; 46(1):52-61. Sharpe AN, Oldach MS, Kaplan JL, Rivas V, Kovacs SL, Hwee DT, Morgan BP, Malik FI, Harris SP, Stern JA. PMID: 36382714; PMCID: PMC10099566.
      View in: PubMed   Mentions: 7     Fields:    Translation:Animals
    41. A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy Participants. JACC Basic Transl Sci. 2022 Aug; 7(8):763-775. Malik FI, Robertson LA, Armas DR, Robbie EP, Osmukhina A, Xu D, Li H, Solomon SD. PMID: 36061336; PMCID: PMC9436819.
      View in: PubMed   Mentions: 15  
    42. Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial. JAMA. 2022 07 19; 328(3):259-269. Lewis GD, Voors AA, Cohen-Solal A, Metra M, Whellan DJ, Ezekowitz JA, Böhm M, Teerlink JR, Docherty KF, Lopes RD, Divanji PH, Heitner SB, Kupfer S, Malik FI, Meng L, Wohltman A, Felker GM. PMID: 35852527; PMCID: PMC9297119.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    43. Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. Eur Heart J. 2022 06 14; 43(23):2212-2220. Solomon SD, Claggett BL, Miao ZM, Diaz R, Felker GM, McMurray JJV, Metra M, Corbalan R, Filippatos G, Goudev AR, Mareev V, Serpytis P, Suter T, Yilmaz MB, Zannad F, Kupfer S, Heitner SB, Malik FI, Teerlink JR. PMID: 35325102.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    44. Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. Circ Heart Fail. 2022 05; 15(5):e008970. Lewis GD, Docherty KF, Voors AA, Cohen-Solal A, Metra M, Whellan DJ, Ezekowitz JA, Ponikowski P, Böhm M, Teerlink JR, Heitner SB, Kupfer S, Malik FI, Meng L, Felker GM. PMID: 35236099.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    45. Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. JAMA Cardiol. 2022 01 01; 7(1):26-34. Felker GM, Solomon SD, Claggett B, Diaz R, McMurray JJV, Metra M, Anand I, Crespo-Leiro MG, Dahlström U, Goncalvesova E, Howlett JG, MacDonald P, Parkhomenko A, Tomcsányi J, Abbasi SA, Heitner SB, Hucko T, Kupfer S, Malik FI, Teerlink JR. PMID: 34643642; PMCID: PMC8515258.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    46. Novel Small-Molecule Troponin Activator Increases Cardiac Contractile Function Without Negative Impact on Energetics. Circ Heart Fail. 2022 03; 15(3):e009195. He H, Baka T, Balschi J, Motani AS, Nguyen KK, Liu Q, Slater R, Rock B, Wang C, Hale C, Karamanlidis G, Hartman JJ, Malik FI, Reagan JD, Luptak I. PMID: 34743528; PMCID: PMC8920024.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimals
    47. Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function. J Med Chem. 2021 10 28; 64(20):14930-14941. Collibee SE, Bergnes G, Chuang C, Ashcraft L, Gardina J, Garard M, Jamison CR, Lu K, Lu PP, Muci A, Romero A, Valkevich E, Wang W, Warrington J, Yao B, Durham N, Hartman J, Marquez A, Hinken A, Schaletzky J, Xu D, Hwee DT, Morgans D, Malik FI, Morgan BP. PMID: 34636234.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    48. Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy. J Med Chem. 2021 10 14; 64(19):14142-14152. Chuang C, Collibee S, Ashcraft L, Wang W, Vander Wal M, Wang X, Hwee DT, Wu Y, Wang J, Chin ER, Cremin P, Zamora J, Hartman J, Schaletzky J, Wehri E, Robertson LA, Malik FI, Morgan BP. PMID: 34606259.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    49. Pharmacokinetics, Tolerability, and Safety of Single and Multiple Omecamtiv Mecarbil Doses in Healthy Japanese and Caucasian Subjects. Eur J Drug Metab Pharmacokinet. 2021 Nov; 46(6):759-770. Trivedi A, Malik FI, Mackowski M, Hutton S, Aoki M, Abbasi S, Dutta S, Lee E. PMID: 34415561.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    50. Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of reldesemtiv in ALS: post hoc analyses of a randomized, double-blind, placebo-controlled clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2022 05; 23(3-4):263-270. Rudnicki SA, Andrews JA, Genge A, Jackson C, Lechtzin N, Miller TM, Cockroft BM, Malik FI, Meng L, Wei J, Wolff AA, Shefner JM, FORTITUDE-ALS STUDY GROUP. PMID: 34218726.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    51. Correction to: Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study. Neurotherapeutics. 2021 Jul; 18(3):2130. Rudnicki SA, Andrews JA, Duong T, Cockroft BM, Malik FI, Meng L, Wei J, Wolff AA, Genge A, Johnson NE, Tesi-Rocha C, Connolly AM, Darras BT, Felice K, Finkel RS, Shieh PB, Mah JK, Statland J, Campbell C, Habib AA, Kuntz NL, Oskoui M, Day JW. PMID: 34731415; PMCID: PMC8609058.
      View in: PubMed   Mentions: 1     Fields:    
    52. Acute and chronic tirasemtiv treatment improves in vivo and in vitro muscle performance in actin-based nemaline myopathy mice. Hum Mol Genet. 2021 06 26; 30(14):1305-1320. de Winter JM, Gineste C, Minardi E, Brocca L, Rossi M, Borsboom T, Beggs AH, Bernard M, Bendahan D, Hwee DT, Malik FI, Pellegrino MA, Bottinelli R, Gondin J, Ottenheijm CAC. PMID: 33909041; PMCID: PMC8255131.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    53. Pharmacokinetic Evaluation of the CYP3A4 and CYP2D6 Drug-Drug Interaction and CYP3A4 Induction Potential of Omecamtiv Mecarbil: Two Open-Label Studies in Healthy Subjects. Clin Pharmacol Drug Dev. 2022 02; 11(2):185-193. Trivedi A, Malik FI, Jafarinasabian P, Zhang H, Flach S, Abbasi S, Dutta S, Lee E. PMID: 34145992.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    54. Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. J Am Coll Cardiol. 2021 07 13; 78(2):97-108. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Biering-Sørensen T, Böhm M, Bonderman D, Fang JC, Lanfear DE, Lund M, Momomura SI, O'Meara E, Ponikowski P, Spinar J, Flores-Arredondo JH, Claggett BL, Heitner SB, Kupfer S, Abbasi SA, Malik FI, GALACTIC-HF Investigators. PMID: 34015475.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    55. The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF). Eur J Heart Fail. 2021 06; 23(6):1052-1056. Biering-Sørensen T, Minamisawa M, Liu J, Claggett B, Papolos AI, Felker GM, McMurray JJV, Legg JC, Malik FI, Honarpour N, Kurtz CE, Teerlink JR, Solomon SD. PMID: 33826209.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    56. Pathogenic variants in TNNC2 cause congenital myopathy due to an impaired force response to calcium. J Clin Invest. 2021 05 03; 131(9). van de Locht M, Donkervoort S, de Winter JM, Conijn S, Begthel L, Kusters B, Mohassel P, Hu Y, Medne L, Quinn C, Moore SA, Foley AR, Seo G, Hwee DT, Malik FI, Irving T, Ma W, Granzier HL, Kamsteeg EJ, Immadisetty K, Kekenes-Huskey P, Pinto JR, Voermans N, Bönnemann CG, Ottenheijm CA. PMID: 33755597; PMCID: PMC8087209.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    57. Noninvasive ventilation use by patients enrolled in VITALITY-ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2021 11; 22(7-8):486-494. Rudnicki SA, Andrews JA, Bian A, Cockroft BM, Cudkowicz ME, Hardiman O, Malik FI, Meng L, Wolff AA, Shefner JM, VITALITY-ALS STUDY GROUP. PMID: 33792451.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    58. Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study. Neurotherapeutics. 2021 04; 18(2):1127-1136. Rudnicki SA, Andrews JA, Duong T, Cockroft BM, Malik FI, Meng L, Wei J, Wolff AA, Genge A, Johnson NE, Tesi-Rocha C, Connolly AM, Darras BT, Felice K, Shieh PB, Mah JK, Statland J, Campbell C, Habib AA, Kuntz NL, Oskoui M, Day JW, Finkel RS. PMID: 33624184; PMCID: PMC8423982.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    59. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. N Engl J Med. 2021 01 14; 384(2):105-116. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sørensen T, Böhm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlström U, Echeverria LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Li J, Lund M, Macdonald P, Mareev V, Momomura SI, O'Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Varin C, Honarpour N, Abbasi SA, Malik FI, Kurtz CE, GALACTIC-HF Investigators. PMID: 33185990.
      View in: PubMed   Mentions: 212     Fields:    Translation:HumansCTClinical Trials
    60. Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study. Circ Heart Fail. 2020 12; 13(12):e007814. Felker GM, Solomon SD, McMurray JJV, Cleland JGF, Abbasi SA, Malik FI, Zhang H, Globe G, Teerlink JR, COSMIC-HF Investigators. PMID: 33176437; PMCID: PMC7742205.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    61. Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure: The COSMIC-HF Trial. Circ Heart Fail. 2020 12; 13(12):e008007. Biering-Sørensen T, Minamisawa M, Claggett B, Liu J, Felker GM, McMurray JJV, Malik FI, Abbasi S, Kurtz CE, Teerlink JR, Solomon SD. PMID: 33176443.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    62. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. Eur J Heart Fail. 2020 11; 22(11):2160-2171. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sørensen T, Böhm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlström U, Echeverria Correa LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Lund M, Macdonald P, Mareev V, Momomura SI, O'Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Abbasi SA, Varin C, Malik FI, Kurtz CE, GALACTIC-HF Investigators. PMID: 32985088; PMCID: PMC7756903.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    63. Left ventricular systolic ejection time is an independent predictor of all-cause mortality in heart failure with reduced ejection fraction. Eur J Heart Fail. 2021 02; 23(2):240-249. Alhakak AS, Sengeløv M, Jørgensen PG, Bruun NE, Johnsen C, Abildgaard U, Iversen AZ, Hansen TF, Teerlink JR, Malik FI, Solomon SD, Gislason G, Biering-Sørensen T. PMID: 33034122.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    64. A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2021 05; 22(3-4):287-299. Shefner JM, Andrews JA, Genge A, Jackson C, Lechtzin N, Miller TM, Cockroft BM, Meng L, Wei J, Wolff AA, Malik FI, Bodkin C, Brooks BR, Caress J, Dionne A, Fee D, Goutman SA, Goyal NA, Hardiman O, Hayat G, Heiman-Patterson T, Heitzman D, Henderson RD, Johnston W, Karam C, Kiernan MC, Kolb SJ, Korngut L, Ladha S, Matte G, Mora JS, Needham M, Oskarsson B, Pattee GL, Pioro EP, Pulley M, Quan D, Rezania K, Schellenberg KL, Schultz D, Shoesmith C, Simmons Z, Statland J, Sultan S, Swenson A, Berg LHVD, Vu T, Vucic S, Weiss M, Whyte-Rayson A, Wymer J, Zinman L, Rudnicki SA. PMID: 32969758; PMCID: PMC8117790.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    65. Fast skeletal muscle troponin activator CK-2066260 mitigates skeletal muscle weakness independently of the underlying cause. J Cachexia Sarcopenia Muscle. 2020 12; 11(6):1747-1757. Cheng AJ, Ström J, Hwee DT, Malik FI, Westerblad H. PMID: 32954682; PMCID: PMC7749611.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    66. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF. JACC Heart Fail. 2020 04; 8(4):329-340. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Legg JC, Büchele G, Varin C, Kurtz CE, Malik FI, Honarpour N. PMID: 32035892.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    67. Functional Characterization of the Intact Diaphragm in a Nebulin-Based Nemaline Myopathy (NM) Model-Effects of the Fast Skeletal Muscle Troponin Activator tirasemtiv. Int J Mol Sci. 2019 Oct 10; 20(20). Lee EJ, Kolb J, Hwee DT, Malik FI, Granzier HL. PMID: 31658633; PMCID: PMC6829460.
      View in: PubMed   Mentions: 4     Fields:    Translation:Animals
    68. Fast skeletal muscle troponin activator CK-2066260 increases fatigue resistance by reducing the energetic cost of muscle contraction. J Physiol. 2019 09; 597(17):4615-4625. Cheng AJ, Hwee DT, Kim LH, Durham N, Yang HT, Hinken AC, Kennedy AR, Terjung RL, Jasper JR, Malik FI, Westerblad H. PMID: 31246276; PMCID: PMC6851859.
      View in: PubMed   Mentions: 15     Fields:    Translation:AnimalsCells
    69. A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019; 0(0):1-11. Shefner JM, Cudkowicz ME, Hardiman O, Cockcroft BM, Lee JH, Malik FI, Meng L, Rudnicki SA, Wolff AA, Andrews JA, VITALITY-ALS Study Group. PMID: 31081694.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    70. Discovery of Tirasemtiv, the First Direct Fast Skeletal Muscle Troponin Activator. ACS Med Chem Lett. 2018 Apr 12; 9(4):354-358. Collibee SE, Bergnes G, Muci A, Browne WF, Garard M, Hinken AC, Russell AJ, Suehiro I, Hartman J, Kawas R, Lu PP, Lee KH, Marquez D, Tomlinson M, Xu D, Kennedy A, Hwee D, Schaletzky J, Leung K, Malik FI, Morgans DJ, Morgan BP. PMID: 29670700; PMCID: PMC5900333.
      View in: PubMed   Mentions: 8  
    71. VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2018 05; 19(3-4):259-266. Andrews JA, Cudkowicz ME, Hardiman O, Meng L, Bian A, Lee J, Wolff AA, Malik FI, Shefner JM. PMID: 29402141.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    72. Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory. J Am Coll Cardiol. 2018 01 30; 71(4):443-453. O'Connor CM, Psotka MA, Fiuzat M, Lindenfeld J, Abraham WT, Bristow MR, Canos D, Harrington RA, Hillebrenner M, Jessup M, Malik FI, Solomon SD, Stockbridge N, Tcheng JE, Unger EF, Whellan DJ, Zuckerman B, Califf RM. PMID: 29389362.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    73. Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis. JAMA Neurol. 2018 01 01; 75(1):58-64. Andrews JA, Meng L, Kulke SF, Rudnicki SA, Wolff AA, Bozik ME, Malik FI, Shefner JM. PMID: 29181534; PMCID: PMC5833488.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    74. CK-2127107 amplifies skeletal muscle response to nerve activation in humans. Muscle Nerve. 2018 05; 57(5):729-734. Andrews JA, Miller TM, Vijayakumar V, Stoltz R, James JK, Meng L, Wolff AA, Malik FI. PMID: 29150952; PMCID: PMC6681065.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCellsCTClinical Trials
    75. Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil. Nat Commun. 2017 08 04; 8(1):190. Planelles-Herrero VJ, Hartman JJ, Robert-Paganin J, Malik FI, Houdusse A. PMID: 28775348; PMCID: PMC5543065.
      View in: PubMed   Mentions: 104     Fields:    Translation:AnimalsCells
    76. Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference. Cardiovasc Drugs Ther. 2017 Aug; 31(4):445-458. Povsic TJ, Scott R, Mahaffey KW, Blaustein R, Edelberg JM, Lefkowitz MP, Solomon SD, Fox JC, Healy KE, Khakoo AY, Losordo DW, Malik FI, Monia BP, Montgomery RL, Riesmeyer J, Schwartz GG, Zelenkofske SL, Wu JC, Wasserman SM, Roe MT. PMID: 28735360.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    77. New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. Eur J Heart Fail. 2017 06; 19(6):718-727. Cowie MR, Filippatos GS, Alonso Garcia MLA, Anker SD, Baczynska A, Bloomfield DM, Borentain M, Bruins Slot K, Cronin M, Doevendans PA, El-Gazayerly A, Gimpelewicz C, Honarpour N, Janmohamed S, Janssen H, Kim AM, Lautsch D, Laws I, Lefkowitz M, Lopez-Sendon J, Lyon AR, Malik FI, McMurray JJV, Metra M, Figueroa Perez S, Pfeffer MA, Pocock SJ, Ponikowski P, Prasad K, Richard-Lordereau I, Roessig L, Rosano GMC, Sherman W, Stough WG, Swedberg K, Tyl B, Zannad F, Boulton C, De Graeff P. PMID: 28345190.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    78. The Ca2+ sensitizer CK-2066260 increases myofibrillar Ca2+ sensitivity and submaximal force selectively in fast skeletal muscle. J Physiol. 2017 03 01; 595(5):1657-1670. Hwee DT, Cheng AJ, Hartman JJ, Hinken AC, Lee K, Durham N, Russell AJ, Malik FI, Westerblad H, Jasper JR. PMID: 27869319; PMCID: PMC5330873.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCells
    79. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet. 2016 12 10; 388(10062):2895-2903. Teerlink JR, Felker GM, McMurray JJ, Solomon SD, Adams KF, Cleland JG, Ezekowitz JA, Goudev A, Macdonald P, Metra M, Mitrovic V, Ponikowski P, Serpytis P, Spinar J, Tomcsányi J, Vandekerckhove HJ, Voors AA, Monsalvo ML, Johnston J, Malik FI, Honarpour N, COSMIC-HF Investigators. PMID: 27914656.
      View in: PubMed   Mentions: 130     Fields:    Translation:HumansCTClinical Trials
    80. Highly selective inhibition of myosin motors provides the basis of potential therapeutic application. Proc Natl Acad Sci U S A. 2016 11 22; 113(47):E7448-E7455. Sirigu S, Hartman JJ, Planelles-Herrero VJ, Ropars V, Clancy S, Wang X, Chuang G, Qian X, Lu PP, Barrett E, Rudolph K, Royer C, Morgan BP, Stura EA, Malik FI, Houdusse AM. PMID: 27815532; PMCID: PMC5127359.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    81. Incorporating development of a patient-reported outcome instrument in a clinical drug development program: examples from a heart failure program. Health Qual Life Outcomes. 2016 Sep 15; 14(1):131. Wiklund I, Anatchkova M, Oko-Osi H, von Maltzahn R, Chau D, Malik FI, Patrick DL, Spertus J, Teerlink JR. PMID: 27629389; PMCID: PMC5024511.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    82. Patient-Reported Outcomes in Chronic Heart Failure: Applicability for Regulatory Approval. JACC Heart Fail. 2016 10; 4(10):791-804. Psotka MA, von Maltzahn R, Anatchkova M, Agodoa I, Chau D, Malik FI, Patrick DL, Spertus JA, Wiklund I, Teerlink JR. PMID: 27395351.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansPHPublic Health
    83. Reduced force of diaphragm muscle fibers in patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2016 07 01; 311(1):L20-8. Manders E, Bonta PI, Kloek JJ, Symersky P, Bogaard HJ, Hooijman PE, Jasper JR, Malik FI, Stienen GJ, Vonk-Noordegraaf A, de Man FS, Ottenheijm CA. PMID: 27190061; PMCID: PMC4967190.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    84. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. J Am Coll Cardiol. 2016 Mar 29; 67(12):1444-1455. Teerlink JR, Felker GM, McMurray JJV, Ponikowski P, Metra M, Filippatos GS, Ezekowitz JA, Dickstein K, Cleland JGF, Kim JB, Lei L, Knusel B, Wolff AA, Malik FI, Wasserman SM, ATOMIC-AHF Investigators. PMID: 27012405.
      View in: PubMed   Mentions: 103     Fields:    Translation:HumansCTClinical Trials
    85. Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects. Int J Clin Pharmacol Ther. 2016 Mar; 54(3):217-27. Palaparthy R, Banfield C, Alvarez P, Yan L, Smith B, Johnson J, Monsalvo ML, Malik F. PMID: 26709596; PMCID: PMC4776255.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    86. Letter by Teerlink et al Regarding Article, "Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity". Circ Heart Fail. 2015 Nov; 8(6):1141. Teerlink JR, Malik FI, Kass DA. PMID: 26578671; PMCID: PMC4654674.
      View in: PubMed   Mentions: 5     Fields:    Translation:Animals
    87. Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure. J Clin Pharmacol. 2015 Nov; 55(11):1236-47. Vu T, Ma P, Xiao JJ, Wang YM, Malik FI, Chow AT. PMID: 25951506.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    88. High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS). Leukemia. 2015 Sep; 29(9):1928-38. Mohamedali AM, Gäken J, Ahmed M, Malik F, Smith AE, Best S, Mian S, Gaymes T, Ireland R, Kulasekararaj AG, Mufti GJ. PMID: 25943179.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    89. A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis. Neurotherapeutics. 2015 Apr; 12(2):455-60. Sanders DB, Rosenfeld J, Dimachkie MM, Meng L, Malik FI, Tirasemtiv in Myasthenia Gravis Study Group. PMID: 25742919; PMCID: PMC4404445.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCellsCTClinical Trials
    90. The small-molecule fast skeletal troponin activator, CK-2127107, improves exercise tolerance in a rat model of heart failure. J Pharmacol Exp Ther. 2015 Apr; 353(1):159-68. Hwee DT, Kennedy AR, Hartman JJ, Ryans J, Durham N, Malik FI, Jasper JR. PMID: 25678535.
      View in: PubMed   Mentions: 30     Fields:    Translation:AnimalsCells
    91. Tirasemtiv amplifies skeletal muscle response to nerve activation in humans. Muscle Nerve. 2014 Dec; 50(6):925-31. Hansen R, Saikali KG, Chou W, Russell AJ, Chen MM, Vijayakumar V, Stoltz RR, Baudry S, Enoka RM, Morgans DJ, Wolff AA, Malik FI. PMID: 24634285; PMCID: PMC4260123.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    92. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. JACC Heart Fail. 2015 Jan; 3(1):22-29. Greenberg BH, Chou W, Saikali KG, Escandón R, Lee JH, Chen MM, Treshkur T, Megreladze I, Wasserman SM, Eisenberg P, Malik FI, Wolff AA, Shaburishvili T. PMID: 25453536.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    93. Effect of tirasemtiv, a selective activator of the fast skeletal muscle troponin complex, in patients with peripheral artery disease. Vasc Med. 2014 Aug; 19(4):297-306. Bauer TA, Wolff AA, Hirsch AT, Meng LL, Rogers K, Malik FI, Hiatt WR. PMID: 24872402.
      View in: PubMed   Mentions: 3     Fields:    
    94. Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model. PLoS One. 2014; 9(5):e96921. Hwee DT, Kennedy A, Ryans J, Russell AJ, Jia Z, Hinken AC, Morgans DJ, Malik FI, Jasper JR. PMID: 24805850; PMCID: PMC4013064.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansAnimalsCells
    95. Novel drug mechanisms in development for heart failure. Pflugers Arch. 2014 Jun; 466(6):1219-25. Khodjaev SD, Teerlink JR, Malik FI. PMID: 24793049.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    96. Diaphragm fiber strength is reduced in critically ill patients and restored by a troponin activator. Am J Respir Crit Care Med. 2014 Apr 01; 189(7):863-5. Hooijman PE, Beishuizen A, de Waard MC, de Man FS, Vermeijden JW, Steenvoorde P, Bouwman RA, Lommen W, van Hees HW, Heunks LM, Dickhoff C, van der Peet DL, Girbes AR, Jasper JR, Malik FI, Stienen GJ, Hartemink KJ, Paul MA, Ottenheijm CA. PMID: 24684359; PMCID: PMC4225832.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    97. Fast skeletal muscle troponin activator in the dy2J muscular dystrophy model. Muscle Nerve. 2013 Aug; 48(2):279-85. Miciak JJ, Warsing LC, Tibbs ME, Jasper JR, Jampel SB, Malik FI, Tankersley C, Wagner KR. PMID: 23512724.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    98. Deleting exon 55 from the nebulin gene induces severe muscle weakness in a mouse model for nemaline myopathy. Brain. 2013 Jun; 136(Pt 6):1718-31. Ottenheijm CA, Buck D, de Winter JM, Ferrara C, Piroddi N, Tesi C, Jasper JR, Malik FI, Meng H, Stienen GJ, Beggs AH, Labeit S, Poggesi C, Lawlor MW, Granzier H. PMID: 23715096; PMCID: PMC3673460.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansAnimals
    99. Troponin activator augments muscle force in nemaline myopathy patients with nebulin mutations. J Med Genet. 2013 Jun; 50(6):383-92. de Winter JM, Buck D, Hidalgo C, Jasper JR, Malik FI, Clarke NF, Stienen GJ, Lawlor MW, Beggs AH, Ottenheijm CA, Granzier H. PMID: 23572184; PMCID: PMC3865762.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    100. Fast skeletal muscle troponin activation increases force of mouse fast skeletal muscle and ameliorates weakness due to nebulin-deficiency. PLoS One. 2013; 8(2):e55861. Lee EJ, De Winter JM, Buck D, Jasper JR, Malik FI, Labeit S, Ottenheijm CA, Granzier H. PMID: 23437068; PMCID: PMC3577798.
      View in: PubMed   Mentions: 17     Fields:    Translation:AnimalsCells
    101. Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2012 Sep; 13(5):430-8. Shefner J, Cedarbaum JM, Cudkowicz ME, Maragakis N, Lee J, Jones D, Watson ML, Mahoney K, Chen M, Saikali K, Mao J, Russell AJ, Hansen RL, Malik F, Wolff AA, Neals/Cytokinetics Study Team. PMID: 22591195.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    102. Smooth muscle myosin inhibition: a novel therapeutic approach for pulmonary hypertension. PLoS One. 2012; 7(5):e36302. Ho D, Chen L, Zhao X, Durham N, Pannirselvam M, Vatner DE, Morgans DJ, Malik FI, Vatner SF, Shen YT. PMID: 22563487; PMCID: PMC3341368.
      View in: PubMed   Mentions:    Fields:    Translation:Animals
    103. Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat Med. 2012 Feb 19; 18(3):452-5. Russell AJ, Hartman JJ, Hinken AC, Muci AR, Kawas R, Driscoll L, Godinez G, Lee KH, Marquez D, Browne WF, Chen MM, Clarke D, Collibee SE, Garard M, Hansen R, Jia Z, Lu PP, Rodriguez H, Saikali KG, Schaletzky J, Vijayakumar V, Albertus DL, Claflin DR, Morgans DJ, Morgan BP, Malik FI. PMID: 22344294; PMCID: PMC3296825.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansAnimalsCells
    104. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet. 2011 Aug 20; 378(9792):676-83. Cleland JG, Teerlink JR, Senior R, Nifontov EM, Mc Murray JJ, Lang CC, Tsyrlin VA, Greenberg BH, Mayet J, Francis DP, Shaburishvili T, Monaghan M, Saltzberg M, Neyses L, Wasserman SM, Lee JH, Saikali KG, Clarke CP, Goldman JH, Wolff AA, Malik FI. PMID: 21856481.
      View in: PubMed   Mentions: 136     Fields:    Translation:HumansCTClinical Trials
    105. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet. 2011 Aug 20; 378(9792):667-75. Teerlink JR, Clarke CP, Saikali KG, Lee JH, Chen MM, Escandon RD, Elliott L, Bee R, Habibzadeh MR, Goldman JH, Schiller NB, Malik FI, Wolff AA. PMID: 21856480.
      View in: PubMed   Mentions: 103     Fields:    Translation:Humans
    106. Inhibition of smooth muscle myosin as a novel therapeutic target for hypertension. J Pharmacol Exp Ther. 2011 Oct; 339(1):307-12. Zhao X, Ho D, Abarzúa P, Dhar SK, Wang X, Jia Z, Pannirselvam M, Morgans DJ, Malik FI, Vatner SF. PMID: 21784887; PMCID: PMC3186291.
      View in: PubMed   Mentions: 4     Fields:    Translation:Animals
    107. Cardiac myosin activation part 1: from concept to clinic. J Mol Cell Cardiol. 2011 Oct; 51(4):454-61. Malik FI, Morgan BP. PMID: 21616079.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimals
    108. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011 Mar 18; 331(6023):1439-43. Malik FI, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc K, Anderson RL, Sueoka SH, Lee KH, Finer JT, Sakowicz R, Baliga R, Cox DR, Garard M, Godinez G, Kawas R, Kraynack E, Lenzi D, Lu PP, Muci A, Niu C, Qian X, Pierce DW, Pokrovskii M, Suehiro I, Sylvester S, Tochimoto T, Valdez C, Wang W, Katori T, Kass DA, Shen YT, Vatner SF, Morgans DJ. PMID: 21415352; PMCID: PMC4090309.
      View in: PubMed   Mentions: 293     Fields:    Translation:AnimalsCells
    109. Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin. ACS Med Chem Lett. 2010 Dec 09; 1(9):472-7. Morgan BP, Muci A, Lu PP, Qian X, Tochimoto T, Smith WW, Garard M, Kraynack E, Collibee S, Suehiro I, Tomasi A, Valdez SC, Wang W, Jiang H, Hartman J, Rodriguez HM, Kawas R, Sylvester S, Elias KA, Godinez G, Lee K, Anderson R, Sueoka S, Xu D, Wang Z, Djordjevic N, Malik FI, Morgans DJ. PMID: 24900233; PMCID: PMC4007828.
      View in: PubMed   Mentions: 52  
    110. Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail. 2010 Jul; 3(4):522-7. Shen YT, Malik FI, Zhao X, Depre C, Dhar SK, Abarzúa P, Morgans DJ, Vatner SF. PMID: 20498236.
      View in: PubMed   Mentions: 72     Fields:    Translation:Animals
    111. Dobutamine-atropine stress echocardiography for the detection of coronary artery disease in patients with left ventricular hypertrophy. Importance of chamber size and systolic wall stress. Circulation. 2000 Jan 25; 101(3):258-63. Smart SC, Knickelbine T, Malik F, Sagar KB. PMID: 10645921.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    112. Polymorphisms in the umuDC region of Escherichia species. J Bacteriol. 1988 Apr; 170(4):1610-6. Sedgwick SG, Robson M, Malik F. PMID: 2895099; PMCID: PMC211008.
      View in: PubMed   Mentions: 8     Fields:    Translation:Cells
    Fady's Networks
    Concepts (326)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (10)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-13-gbc789823 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.